After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

With a portfolio of 100 leading brands ... counter and vitamins, minerals, and supplements market, serving over 500 million consumers worldwide. Opella’s journey to independence aligns with ...

Sanofi isn’t saying how much it is paying for the OTC rights to Tamiflu in the US ... as Tamiflu continues to decline, with the older brand reduced to just $179m in the first quarter of this ...

Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...

The US Food and Drug Administration (FDA) has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer ...

Vicks once again achieved the top monthly spot for TV impressions, while iSpot noted that pharma brands generated more year-over-year returns from sports and news cables compared to 2023.

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

A line extension of one of Sanofi Indias flagship brand Combiflam, the launch of this new product marks the companys foray into the OTC headache segment in India.On 11 November 2014, Sanofi India ...

Sanofi is one of the biggest players in the Allergy category globally. But in the UK its portfolio was still underrepresented. Aware of a high level of dissatisfaction from UK allergy sufferers with ...